Jennifer Hodge
About
In The Last Decade
Jennifer Hodge
15 papers receiving 1.1k citations
Hit Papers
Peers
Comparison fields: 5 of 86
- Rheumatology 434
- Immunology 384
- Hematology 226
- Oncology 223
- Epidemiology 190
Countries citing papers authored by Jennifer Hodge
This map shows the geographic impact of Jennifer Hodge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jennifer Hodge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jennifer Hodge more than expected).
Fields of papers citing papers by Jennifer Hodge
This network shows the impact of papers produced by Jennifer Hodge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jennifer Hodge. The network helps show where Jennifer Hodge may publish in the future.
Co-authorship network of co-authors of Jennifer Hodge
This figure shows the co-authorship network connecting the top 25 collaborators of Jennifer Hodge. A scholar is included among the top collaborators of Jennifer Hodge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jennifer Hodge. Jennifer Hodge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 14 | |
| 2 | 26 | |
| 3 | 69 | |
| 4 | Real-World Analysis of Dispensed International Units of Coagulation Factor VIII and Resultant Expenditures for Hemophilia A Patients: A Comparison Between Standard Half-Life and Extended Half-Life Products. | 15 |
| 5 | 38 | |
| 6 | 8 | |
| 7 | 91 | |
| 8 | The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. breakdown → | 305 |
| 9 | 141 | |
| 10 | 137 | |
| 11 | 2 | |
| 12 | A Phase I Open Label, Dose Escalation Trial Of QPI-1007 Delivered By A Single Intravitreal (IVT) Injection To Subjects With Low Visual Acuity And Acute Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) | 8 |
| 13 | 253 | |
| 14 | 12 | |
| 15 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.